---
endpoint: analytics
pattern: Financial Services
status: done
latency_ms: 22707
conversation_id: 589dd541-0c49-4eb3-b260-29a6a2e2876f
citations: 0
created: 2026-05-31 20:51:26Z
---

# How does ABC’s valuation compare to peers, and what justifies its premium/discount?

I need clarification before I can run this analysis — **"ABC"** is ambiguous and I don't want to guess at the ticker and waste a research cycle on the wrong company.

The most common interpretations:

| Possibility | Status | Notes |
|---|---|---|
| **AmerisourceBergen** (former ticker `ABC`) | Renamed | Rebranded to **Cencora** in Aug 2023, now trades as **COR** on NYSE |
| **ABC placeholder** | Template | The query reads like a templated prompt with `ABC` as a stand-in for a real ticker |
| **Other "ABC"** | Various | e.g., ABC Arbitrage (FR), AMMB Holdings (MY: AMM), etc. — unlikely matches |

Could you confirm which one you mean? A few ways to disambiguate:

1. **Did you mean Cencora (COR)?** — the US pharmaceutical distributor formerly known as AmerisourceBergen. I'll run a valuation comp vs. McKesson (MCK) and Cardinal Health (CAH).
2. **Did you mean a different ticker?** — please share the ticker symbol or full company name.
3. **Was "ABC" a placeholder in a template?** — if so, paste the actual ticker you want analyzed.

Once confirmed, I'll pull:
- **Valuation multiples** (P/E, EV/EBITDA, P/S, P/B, FCF yield, PEG) — fwd and trailing
- **Peer set** (sector + size matched)
- **Growth + margin + ROIC** to contextualize the multiple
- **Internal research views** (RMS) on target multiples / premium-discount drivers
- **Recent transcript / sell-side commentary** on what management and the Street attribute the gap to

---
**Sources**

No external sources used — clarification request only.

